The standard of NAD measuring
Total raised: $3.89M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 22.08.2024 | Series A | $3.89M | - |
Mentions in press and media 5
| Date | Title | Description |
| 22.08.2024 | NADMED raises €3.5M to bring NAD tests to international markets, advancing personalized treatment options | NADMED raises €3.5M to bring NAD tests to international markets, advancing personalized treatment options Thu, Aug 22, 2024 10:30 CET Report this content Finnish biotech company NADMED has developed the first test to measure all four bodily... |
| 22.08.2024 | Biotech NADMED raises €3.5M series A for 'NAD' vitals testing | Finnish biotech company NADMED has raised €3.5M for its blood testing technology. The round was led by Finnish science-based startup investor Nordic Science Investments (NSI). Additional funding was secured from previous investors Voima Ven... |
| 22.08.2024 | Finnish biotech NADMED raises €3.5 million Series A for vitamin B3 deficiencies testing | Helnsinki-based NADMED has closed a €3.5 million series A round to fund its entry to the U.S. and other international markets with its proprietary nicotinamide adenine dinucleotide (NAD) measurement technology that may help clinicians estab... |
| 22.08.2024 | Nadmed Raises €3.5M in Series A Funding | Nadmed, a Helsinki, Finland-based biotech company developing a testing method to measure all four NADs*, raised €3.5M in Series A funding. The round was led by Nordic Science Investments (NSI) with participation from previous investors Voim... |
| - | NADMED | “The standard of NAD measuring” |